



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Stephen J. Chudzik et al.

Serial No. 09/989,033

Filed: 21 November 2001

For: BIOACTIVE AGENT RELEASE  
COATING

To: Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

) Our Ref. 9896.129.3.1.1

)

) Examiner: Michener

)

) Art Unit: 1762

)

)

)

)

)

)

I hereby certify that this correspondence is being:

☒ deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

☐ facsimile transmitted to the Patent and Trademark Office

☐ hand delivered to the Patent and Trademark Office

on this 23 day of March 2004

By: Marilyn E. Thompson

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT  
BEFORE MAILING DATE OF EITHER A FINAL ACTION  
OR NOTICE OF ALLOWANCE (37 CFR 1.97(c))**

The supplemental information disclosure statement transmitted herewith is being filed after three months of the filing date of this national application or the date of entry of the national stage as set forth in § 1.491 in an international application or after the mailing date of the first Office action on the merits, whichever event occurred last but before the mailing date of either (1) a final action under § 1.113; or (2) a notice of allowance under § 1.311, whichever occurs first.

**CERTIFICATION OR FEE**

Accompanying this transmittal is the fee set forth in 37 CFR 1.17(p) for submission of an information disclosure statement under § 1.97(c).

**FEE PAYMENT**

Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an information disclosure statement under § 1.97(c).

METHOD OF PAYMENT OF FEE

[ ] Attached is a check in the amount of \$180.00.


[X] Charge account 06-1910 in the amount of \$180.00.

If any additional fees are due, please charge Account 06-1910.

Dated:

23 MAR 2004

Respectfully submitted,



Philip M. Goldman  
Registration No. 31,162  
Fredrikson & Byron, P.A.  
4000 Pillsbury Center  
200 South Sixth Street  
Minneapolis, MN 55402-1425  
(612) 492-7088  
Customer No. 022859

PMG/SUPP IDS  
09/989,033  
2928452



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Stephen J. Chudzik et al.

Serial No. 09/989,033

Filed: 21 November 2001

For: BIOACTIVE AGENT RELEASE  
COATING

To: Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

) Our Ref. 9896.129.3.1.1

)

) Examiner: Michener

)

) Art Unit: 1762

)

)

)

)

)

I hereby certify that this correspondence is being:

☒ deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

☐ facsimile transmitted to the Patent and Trademark Office

☐ hand delivered to the Patent and Trademark Office

on this 23 day of March 2004

By

Madeley E. Thompson

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

SIR:

In accordance with the duty of disclosure, a completed Form PTO-1449 is enclosed.

Consideration of each of the listed references by the Examiner is respectfully requested.

Applicant also respectfully requests that an initialed copy of Form PTO-1449 indicating such consideration be returned with the next Official Action, as set forth in MPEP 609.

This Supplemental Information Disclosure Statement includes literature and non-US patent references and is being submitted concurrently with an Electronic Information Disclosure Statement that includes US patent references.

By submitting these references, applicant does not admit that the references are prior art to or material to this application, and reserves the right to establish that any reference is not prior art. Applicant does not represent that the references have been reviewed in detail; there may be details in the references of which applicant is unaware.


03/29/2004 WARDELRI 00000132 061910 09989033

01 FC:1806 180.00 DA

The Commissioner is hereby authorized to charge any additional filing fees required to  
Deposit Account No. 061910.

Dated: 23 MAR 2004

Respectfully submitted,



Philip M. Goldman  
Registration No. 31,162  
Fredrikson & Byron, P.A.  
4000 Pillsbury Center  
200 South Sixth Street  
Minneapolis, MN 55402-1425  
(612) 492-7088  
Customer No. 022859

PMG/SUPP IDS  
09/989,033  
2928452

# INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.

9896.129.3.1.1

SERIAL NO.

09/989,033

APPLICANT

Chudzik et al.

FILING

21 November 2001

GROUP

1762

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	EP 0 604 022	6/1994	EP				
	EP 0 716 836	6/1996	EP				
	EP 0 734 721	10/1996	EP				
	EP 0 747 069	1/1998	EP				
	EP 0 945 148	9/1999	EP				

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Brown LR, Edelman ER, Fischel-Ghodsian F, Langer R, Characterization of glucose-mediated insulin release from implantable polymers, Pharm Sci 1996 Dec; 85 (12): 1341-5.
	Catz P, Friend DR, In vitro evaluations of transdermal levonorgestrel, Drug Des Deliv, 1990, May; 6 (1): 49-60.
	Edelman ER, Simons M, Sirois MG, Rosenberg RD, c-myc in vasculoproliferative disease, Circ Res 1995 Feb; 76(2): 176-82.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

# INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.

9896.129.3.1.1

SERIAL NO.

09/989,033

APPLICANT

Chudzik et al.

FILING

21 November 2001

GROUP

1762

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	EP 0 879 595	11/1998	EP				
	EP 1 174 157	1/2002	EP				
	WO 91/12779	9/1991	WO				
	WO 92/11895	7/1992	WO				
	WO 92/15286	9/1992	WO				

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Eliaz R, Wallach D, Kost J, Long-term protection against the effects of tumor necrosis factor by controlled delivery of the soluble p55 TNF receptor, Cytokine, 1996, Jun; 8(6): 482-7.
	Flemmig TF, Weinacht S, Rudiger S, Rumetsch M, Jung A, Klaiber B, Adjunctive controlled topical application of tetracycline HCl in the treatment of localized persistent or recurrent periodontitis. Effects on clinical parameters and elastase-alpha1-proteinase inhibitor in gingival crevicular fluid, J Chin Periodontol 1996 OCT; 23 (10):914-21.
	Folkman J, How the field of controlled-release technology began, and its central role in the development of angiogenesis research, Biomaterials, 1990, Nov; 11 (9): 615-8.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.

9896.129.3.1.1

SERIAL NO.

09/989,033

APPLICANT

Chudzik et al.

FILING

21 November 2001

GROUP

1762

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 94/21308	9/1994	WO				
	WO 94/21309	9/1994	WO				
	WO 95/03036	2/1995	WO				
	WO 98/17331	4/1998	WO				
	WO 99/38546	8/1999	WO				

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Friling R, Yassur Y, Levy R, Kost J. Schwartz B, Mikhailowsky R, Lamprecht SA, A role of transforming growth factor-beta 1 in the control of corneal neovascularization, In Vivo 10, 59-64 (1996).
	Goodson JM, Hogan PE, Dunham SL, Clinical responses following periodontal treatment by local drug delivery, J Periodontal 1985 Nov; 56 (11 Suppl): 81-7.
	Huland E, Falk B, Hubner D, Huland H, In vivo system to detect long-term continuous release of bioactive interleukin-2 by immunopharmacological depot preparations in nude mice with human tumors, Int. J. Cancer, 1995, 62, 605-9.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.





<b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)				ATTY. DOCKET NO. 9896.129.3.1.1		SERIAL NO. 09/989,033	
				APPLICANT Chudzik et al.			
				FILING 21 November 2001		GROUP 1762	

OIPE  
 MAR 26 2004  
 JCS  
 PATENT & TRADEMARK OFFICE


U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	

FOREIGN PATENT DOCUMENTS								
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION		
						YES	NO	
	WO 01/87374							
	WO 01/87375							
	WO 01/87376							
	WO 02/26139	4/2002	WO					
	WO 02/26271	4/2002	WO					

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
		Ozaki H, Hayashi H, Vinorel SA, Moromizato Y, Campochiaro PA, Oshima K, Intravitreal sustained release of VEGF causes retinal neovascularization in rabbits and breakdown of the blood-retinal barrier in rabbits and primates, Exp Eye Res, 1997, 64, 505-17.
		Sellke FW, Li J, Stamler A, Lopez JJ, Thomas KA, Simons M, Angiogenesis induced by acidic fibroblast growth factor as an alternative method of revascularization for chronic myocardial ischemia, Surgery 1996 Aug; 120 (2): 182-8.
		Suzuki, T. et al. Stent-based delivery of sirolimus release. Circulation 2001, 104: 1188-1193.

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)

ATTY. DOCKET NO.

9896.129.3.1.1

SERIAL NO.

09/989,033

APPLICANT

Chudzik et al.

FILING

21 November 2001

GROUP

1762

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

**FOREIGN PATENT DOCUMENTS**

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 02/26281	4/2002	WO				
	WO 03/022323	3/2003	WO				
	WO 03/064015	8/2003	WO				
	WO 04/000267	12/2003	WO				
	JP 09194347A	7/1997	JP				


**OTHER DOCUMENTS** (Including Author, Title, Date, Pertinent Pages, Etc.)

	Jafary, F, et al Point-Counterpoint: Drug Eluting Stent Euphoria
	Morice et al, A Randomized Comparison of a Sirolimus-Eluting Stent, N Engl J Med, 2002 June; 346, 1773-1780
	Raman et al, Coated Stents: Local Pharmacology, Semin Intervent Cardiol 1998: 3: 133-137

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.

9896.129.3.1.1

SERIAL NO.

09/989,033

APPLICANT

Chudzik et al.

FILING

21 November 2001

GROUP

1762

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
					YES	NO
JP 2036882	1990	JP				


## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Whelan et al, Mechanisms of Drug Loading and Release Kinetics, Semin Intervent Cardiol 1998; 3: 127-131
	Klugherz et al, Twenty-eight-day Efficacy and Phamacokinetics, Coronary Artery Disease 2002 13 (3)
	Regar et al, Stent Development and Local Drug Delivery, British Med Bulletin 2001; 59: 227-48

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)

ATTY. DOCKET NO.

9896.129.3.1.1

SERIAL NO.

09/989,033

APPLICANT

Chudzik et al.

FILING

21 November 2001

GROUP

1762

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

**FOREIGN PATENT DOCUMENTS**

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

		Serruys et al., Rapamycin Eluting Stent: the Onset of a New Era in Interventional Cardiology, Heart 2002 (87) 305-307

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.